HNF is proud to announce that for the fifth year in a row, we have been featured in the annual Rare Neurological Disease Special Report.
StarWise Therapeutics & HNF Form A Strategic Alliance to Bring a NextGen HDAC6 Drug Therapy to CMT2A (MFN2) Patients
HNF has been committed to funding HDAC inhibitor research since 2014.
HNF takes action and joins genomics revolution for CMT and rare forms of IN.
Exciting news for the CMT patient community with the first potential treatment ever!
HNF and Acceleron Pharma have been collaborating since January, 2016. Acceleron Pharma is a ”clinical stage biopharmaceutical company.”
HNF presenting and attending prestigious conferences worldwide.
HNF launches GRIN with 4 online clinical studies that are important as we continue with our therapy development pipelines.
2018 was a pivotal year for the Hereditary Neuropathy Foundation (HNF) and the entire Charcot-MarieTooth (CMT) Community.
True Reply’s Voice Activated Technology is an accessible and innovative new platform that captures the patient’s experience with CMT in their own words.
Help us to improve outcome measures, develop biomarkers and improve patient care by joining the Global Registry for Inherited Neuropathies
There are those situations in life where you are destined to meet and for me, meeting Dr. Jahannaz Dastgir — “Naz for short” — was one of them.
HNF would like to announce, with great pleasure, that it has been invited to participate in the Inherited Neuropathy Consortium (INC), one of 22 groups under the Rare Diseases Clinical Research Network.